Global health vie...
Follow
Find
89 views | +0 today
Scooped by slim slama
onto Global health views-Access to Medicines and IP
Scoop.it!

The Battle Over Generic Drugs in India (and elsewhere) | Work In ...

The Battle Over Generic Drugs in India (and elsewhere) | Work In ... | Global health views-Access to Medicines and IP | Scoop.it
A few days ago, in a courtroom in India, a landmark ruling was made that could impact future legal battles over the sale of generic versions of expensive medications in India. When the Delhi High Court rules that Cipla, the ...
more...
No comment yet.
Global health views-Access to Medicines and IP
A compilation of documents on access to medicines and intellectual property rights
Curated by slim slama
Your new post is loading...
Scooped by slim slama
Scoop.it!

Global pharma cos take Interpol's assistance to combat counterfeit medicines - pharmabiz.com

Global pharma cos take Interpol's assistance to combat counterfeit medicines pharmabiz.com An essential part of the programme is to raise public awareness of the dangers of fake drugs, particularly for people buying medicines online.
more...
No comment yet.
Scooped by slim slama
Scoop.it!

How to achieve international action on falsified and substandard medicines | BMJ

How to achieve international action on falsified and substandard medicines | BMJ | Global health views-Access to Medicines and IP | Scoop.it
more...
No comment yet.
Scooped by slim slama
Scoop.it!

Pharma Executive To Head Gates’ Global Health Program | Intellectual Property Watch

Pharma Executive To Head Gates’ Global Health Program | Intellectual Property Watch | Global health views-Access to Medicines and IP | Scoop.it
The Bill & Melinda Gates Foundation today announced that Trevor Mundel has been named president of the foundation's Global Health Program.
more...
No comment yet.
Scooped by slim slama
Scoop.it!

Hearing Update: Novartis argues section 3(d) not intended to ...

While referring to the provisions of compulsory licensing, Mr Subramaniam pointed out the requirement of local working and said that once a patent is granted in India, a manufacturing facility could be set up in India.
more...
No comment yet.
Scooped by slim slama
Scoop.it!

Delhi High Court dismisses Roche's patent suit against Cipla - The Economic Times

Delhi High Court dismisses Roche's patent suit against Cipla - The Economic Times | Global health views-Access to Medicines and IP | Scoop.it

The Economic Times: The Delhi HC dismissed Hoffmann-La Roche's suit accusing Cipla of infringing the Swiss company's patent for its lung cancer medicine Tarceva.

more...
No comment yet.
Scooped by slim slama
Scoop.it!

Geneva Fall/Winter 2012: What's in store at the WHO, WIPO and WTO | Knowledge Ecology International

Geneva Fall/Winter 2012: What's in store at the WHO, WIPO and WTO | Knowledge Ecology International | Global health views-Access to Medicines and IP | Scoop.it

As Geneva awakes from its summer slumber post-Jeûne genevois (6 September 2012), the following conferences and negotiations are expected to shape the knowledge governance landscape in the second semester of 2012 at WHO, WIPO and WTO. Here is a list of upcoming meeting of relevance to public health, innovation, access and IPs compiled by Thiru Balasubramaniam,  the Geneva Representative of Knowledge Ecology International. Check also thiru's blog full of interesting articles: http://keionline.org/blog/thiru

more...
No comment yet.
Scooped by slim slama
Scoop.it!

IP and Access to Medicines Thirld World Network publications on the topic

IP and Access to Medicines Thirld World Network publications on the topic | Global health views-Access to Medicines and IP | Scoop.it
more...
No comment yet.
Scooped by slim slama
Scoop.it!

Planet hope - India: the generic drug war

Planet hope - India is the world's largest manufacturer of generic medicines. But a Supreme Court decision could upend the industry, the result of a long legal battle between a giant pharmaceutical company and advocates of generic drugs. What would the consequences be for millions of sick people around the world?

Hannah Moffat brings you inspiring stories on how communities around the world are fighting poverty, illness and empowering children to live in a better world.

more...
No comment yet.
Scooped by slim slama
Scoop.it!

MSF Access Campaign: Infographics: Big pharma's continued attack on India, 'pharmacy of the developing world'

MSF Access Campaign: Infographics: Big pharma's continued attack on India, 'pharmacy of the developing world' | Global health views-Access to Medicines and IP | Scoop.it

Novartis and Bayer are both charging exhorbitant prices for medicines in India as they continue their fight against the country's patent law that puts people over profits in the name of access to affordable medicines. These cases both could have a major impact on MSF's work in the field, as we rely heavily on affordable medicines produced in India to do our work.

more...
No comment yet.
Scooped by slim slama
Scoop.it!

Novartis, Drop the Case! MSF Access Campaign to protect acces to generic medicines

Novartis, Drop the Case! MSF Access Campaign to protect acces to generic medicines | Global health views-Access to Medicines and IP | Scoop.it

MSF @Novartis Drop the Case Campaign special protest event #FreezeNovartis in downtown Geneva on Wednesday 19th http://on.fb.me/SHrFF3

more...
No comment yet.
Scooped by slim slama
Scoop.it!

Access approach is more organised | Access to Medicine Index

Access approach is more organised | Access to Medicine Index | Global health views-Access to Medicines and IP | Scoop.it
Access approach is more organized

Companies are becoming more organised in their approach and the Index leaders are increasingly coming to view access as a strategic issue. Access to medicine has landed in more boardrooms.
The 2012 Index finds that more than 60% of companies now have direct board ownership of access to medicine and that more companies are setting meaningful targets. Among the highest-ranked companies, leadership is coming from the very top, and there’s an ever-increasing organisational focus. Dedicated access functions are being established and incentives to deliver access objectives are becoming more common, and are increasingly supported by performance management systems. For instance, Index leader GlaxoSmithKline has, since the last Index report in 2010, established a Developing Countries and Market Access unit as a department dedicated to access, bringing all its businesses in Least Developed Countries under one umbrella, supported by a new lower price/higher volume business model. Notably, the bonus system for managers in this new unit is structured in a fundamentally different way, to reward volume growth rather than profit growth. Three other companies in the top five - Johnson & Johnson, Sanofi and Gilead – as well as Eisai, have also created similar dedicated departments.


more...
No comment yet.
Scooped by slim slama
Scoop.it!

Here's why 10 percent of the developing world's drugs are fake - Washington Post (blog)

Here's why 10 percent of the developing world's drugs are fake - Washington Post (blog) | Global health views-Access to Medicines and IP | Scoop.it
The fake or faulty meds circulate through the globalized drug trade, originating sometimes from organized crime groups and other times from middling...
more...
No comment yet.
Rescooped by slim slama from PharmEmerge
Scoop.it!

Massive profits for India pharma companies from U.S. sales

Massive profits for India pharma companies from U.S. sales | Global health views-Access to Medicines and IP | Scoop.it

by Steven Lott

World Health Advocacy

Oct 3, 2012

 

Major pharmaceutical companies from India are reporting huge increases in profits generated primarily by increased penetration into the United Sates pharmaceutical market.

In August, India pharmaceutical major, Wockhardt, reported a 95% increase in consolidated net profit. According to Wockhardt, in the most recent quarter sales in the United States and the EU “contributed 71per cent of consolidated revenue."

Similarly India pharmaceutical majors Lupin, Sun Pharma, and Dr. Reddy’s also are reporting massive growth and profits primarily from the U.S. market.

In the last year Dr Reddy’s sales to the U.S. increased 133%. Net profits are up 88% and revenue from US sales were 44% of total sales

For Lupin, in the past year US sales grew 63% . Profits are up 67% and revenue from US sales is 40 % of total sales revenue

Sun Pharma sales in US are up 104% for the year and revenue from sales in the U.S. account for 39 per cent of Sun’s total sales revenue. Sun’s profit after taxes for the last year is 39%


Via Christopher Ward
more...
No comment yet.
Scooped by slim slama
Scoop.it!

The Battle Over Generic Drugs in India (and elsewhere) | Work In ...

The Battle Over Generic Drugs in India (and elsewhere) | Work In ... | Global health views-Access to Medicines and IP | Scoop.it
A few days ago, in a courtroom in India, a landmark ruling was made that could impact future legal battles over the sale of generic versions of expensive medications in India. When the Delhi High Court rules that Cipla, the ...
more...
No comment yet.
Scooped by slim slama
Scoop.it!

TRIPS and its place in international intellectual property law making-IP Justice

TRIPS and its place in international intellectual property law making-IP Justice | Global health views-Access to Medicines and IP | Scoop.it

An article on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) from the IP Justice, an international civil liberties organization promoting balanced intellectual property laws and free expression

more...
No comment yet.
Scooped by slim slama
Scoop.it!

WIPO Drug Research Project Strikes First Agreements | Intellectual Property Watch

WIPO Drug Research Project Strikes First Agreements | Intellectual Property Watch | Global health views-Access to Medicines and IP | Scoop.it
A World Intellectual Property Organization project aimed at expanding research on diseases occurring predominately in developing countries using IP-protected material has announced its first research agreements.
more...
No comment yet.
Scooped by slim slama
Scoop.it!

Patents | Universities Allied for Essential Medicines

Patents | Universities Allied for Essential Medicines | Global health views-Access to Medicines and IP | Scoop.it

Patents give their owners exclusive rights to the production, use, or sale of a product. We grant these rights (usually for 20 years) to inventors when their invention is new, useful, and not obvious. These rights can be transferred or shared at the owner's discretion.

The idea is that patents allow their owners to charge higher prices than they could get if everyone was allowed to sell their product. Product development can be an expensive process, so this provides an important economic incentive to develop new useful products. Ultimately, innovation is paid for by those who buy the new product at the elevated price.

There are two major weaknesses to this approach to funding innovation:

Anyone who can't afford the asking price will be unable to access the product, even if the asking price is higher than the actual manufacturing price.
Other inventors must pay a premium to use this new product in their research, or may not be allowed to use it at all, so further innovation is hampered or outright blocked.

more...
No comment yet.
Scooped by slim slama
Scoop.it!

Generic Drugs: Hands off Our Medicine MSF Campaign

With the "Hands off Our Medicine" campaign, MSF is attempting to counteract policies that could restrict access to generic medicines in the developing world,...
more...
No comment yet.
Scooped by slim slama
Scoop.it!

India's patent laws under pressure : The Lancet Special Report

India's patent laws under pressure : The Lancet Special Report | Global health views-Access to Medicines and IP | Scoop.it

In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements.

The report, which is published today (Monday), highlights legal challenges by two pharmaceutical companies, Bayer and Novartis, to key provisions of India's Patents Act. Bayer's appeal was heard last week, and the Indian Supreme Court is due to hear Novartis' appeal tomorrow (11th September).

In their report, "India's patent laws under pressure", Peter Roderick, a barrister, and Allyson Pollock, Professor of Public Health Research and Policy, both from the Centre for Primary Care and Public Health at Queen Mary, University of London, say that the Bayer and Novartis cases "are seeking to undermine public health considerations aimed at improving access and therapeutic advantage".

They conclude: "There are many problems facing access to and rational use of medicines in India but the provisions within the country's patent laws, if more extensively and properly applied, should help rather than hinder such access. India's laws and experiences could provide a useful example for low-income and middle-income countries worldwide."

The report outlines the history and details of the two cases, including an analysis of some of the legal background to the actions.

more...
No comment yet.